Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Ana Maria Chadwick - Executive VP & CFO Ashley A. McEvoy - CEO, President & Director Eric Benjamin - Executive VP, Chief Product & Customer Experience Officer June Lazaroff - Senior Director of Investor Relations Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Issie Kirby - Redburn (Europe) Limited, Research Division Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Jeffrey D.
Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates
Insulet (PODD) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.55 per share a year ago.
Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain PODD Stock in Your Portfolio Now
Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.
Insulet Gains 78.5% in a Year: What's Driving the Stock?
PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.
Here's Why Insulet (PODD) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer
Insulet Corporation's NASDAQ: PODD recent outperformance has caught investors' attention and has earned it a designation as a top performer on the S&P 500.
Outlier Money Flows Lift Insulet
Big Money buying shares of Insulet Corporation (PODD).
